[go: up one dir, main page]

AU7628696A - Polyvalent anti-dengue vaccine - Google Patents

Polyvalent anti-dengue vaccine

Info

Publication number
AU7628696A
AU7628696A AU76286/96A AU7628696A AU7628696A AU 7628696 A AU7628696 A AU 7628696A AU 76286/96 A AU76286/96 A AU 76286/96A AU 7628696 A AU7628696 A AU 7628696A AU 7628696 A AU7628696 A AU 7628696A
Authority
AU
Australia
Prior art keywords
dengue vaccine
polyvalent anti
polyvalent
dengue
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU76286/96A
Other versions
AU718740B2 (en
Inventor
Vincent Deubel
Isabelle Staropoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of AU7628696A publication Critical patent/AU7628696A/en
Application granted granted Critical
Publication of AU718740B2 publication Critical patent/AU718740B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU76286/96A 1995-11-14 1996-11-14 Polyvalent anti-dengue vaccine Ceased AU718740B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513489A FR2741077B1 (en) 1995-11-14 1995-11-14 VERSATILE ANTI-DENGUE VACCINE
FR95/13489 1995-11-14
PCT/FR1996/001801 WO1997018311A1 (en) 1995-11-14 1996-11-14 Polyvalent anti-dengue vaccine

Publications (2)

Publication Number Publication Date
AU7628696A true AU7628696A (en) 1997-06-05
AU718740B2 AU718740B2 (en) 2000-04-20

Family

ID=9484557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76286/96A Ceased AU718740B2 (en) 1995-11-14 1996-11-14 Polyvalent anti-dengue vaccine

Country Status (9)

Country Link
EP (1) EP0861324A1 (en)
JP (1) JP2000500969A (en)
KR (1) KR19990067581A (en)
CN (1) CN1202201A (en)
AU (1) AU718740B2 (en)
BR (1) BR9611477A (en)
CA (1) CA2235334A1 (en)
FR (1) FR2741077B1 (en)
WO (1) WO1997018311A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
KR20010022452A (en) * 1997-07-31 2001-03-15 추후제출 Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (en) * 1997-08-14 2001-04-06 Pasteur Institut USE OF RECOMBINANT ENVELOPE PROTEINS FOR THE DIAGNOSIS OF DENGUE VIRUS
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CN101519657B (en) * 2000-02-10 2014-08-20 美国国有健康与人类服务部 Full-length infectious cDNA clones of tick borne flavivirus
JP5848243B2 (en) * 2009-06-01 2016-01-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Immunogenic composition against dengue virus
BR112017004008A2 (en) * 2014-09-01 2018-01-23 International Centre For Genetic Engineering And Biotechnology recombinant polypeptide, nucleic acid sequence, host cell, bionanoparticle, methods for producing a bionanoparticle and for treating or preventing dengue virus, and vaccine.
TWI852899B (en) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 Vaccine compositions
CN106290847A (en) * 2015-05-13 2017-01-04 上海凯创生物技术有限公司 A kind of dengue virus NS1 antigen emulsion technique detection kit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003161A1 (en) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease

Also Published As

Publication number Publication date
JP2000500969A (en) 2000-02-02
BR9611477A (en) 1999-12-28
EP0861324A1 (en) 1998-09-02
KR19990067581A (en) 1999-08-25
AU718740B2 (en) 2000-04-20
FR2741077A1 (en) 1997-05-16
CA2235334A1 (en) 1997-05-22
CN1202201A (en) 1998-12-16
WO1997018311A1 (en) 1997-05-22
FR2741077B1 (en) 1998-01-23

Similar Documents

Publication Publication Date Title
AU4878096A (en) Hepatitis b vaccine
AU5399696A (en) Amusement device
AU7662196A (en) Radiation-delivery device
GB9513261D0 (en) Vaccines
AU4780596A (en) Hemi-wheeled walker
AU4877896A (en) Preparation
AU7114296A (en) Improved denture fixative
AU7518996A (en) Practice device
AU6194396A (en) Bacteriocin
AU670739B3 (en) Candy-dispensing device
AU7628696A (en) Polyvalent anti-dengue vaccine
AU6820796A (en) Antigenic preparations
AU3552797A (en) Vaccine preparations
AU7520396A (en) Abl-interactor protein
AU5819096A (en) Hf-anti-interference device
AU5284296A (en) Immune-evading proteins
AU6153396A (en) E6ap-binding proteins
AU4727196A (en) Tie device
AU7231596A (en) Spacer
AU1205497A (en) Vaccine component
AU1092097A (en) Hair-retaining device
AU7623296A (en) Microcellulose-based preparations
AU6826896A (en) Vaccines
AU6293896A (en) Sarcocystis vaccine
AU5277896A (en) Swell-attenuating device

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired